Skip to content

Study · Systematic review · 2019

4 results

Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.

Kanters S, Wilkinson L, Vrazic H, Sharma R, Lopes S, Popoff E, Druyts E

BMJ open23 Jul 2019Cited by 11 (Europe PMC)

PMID31340953 (opens in a new tab)PMCIDPMC6661926 (opens in a new tab)DOI10.1136/bmjopen-2018-023458 (opens in a new tab)PepBankPUB-31340953
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes on 1-2 oral drugs, network meta-analysis found once-weekly semaglutide 1.0 mg lowered HbA1c more than SGLT-2 inhibitors, by 0.56% to 0.95%.

    In plain wordsIn adults with type 2 diabetes, indirect comparison found weekly semaglutide lowered HbA1c more than SGLT-2 inhibitor pills.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change versus SGLT-2 inhibitors
    Study

    n: not reported in source

    Comparator
    SGLT-2 inhibitors
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.0 mg once weekly · 26 (±4) weeksAs given in this study (human).

    Measurements

    HbA1c mean difference
    −0.56%
    vs canagliflozin 300 mg
    HbA1c mean difference
    −0.95%
    vs dapagliflozin 5 mg

    Source sentences

    Summary
    The mean differences (MD) in change from baseline in HbA1c of once-weekly semaglutide 1.0 mg versus SGLT-2is ranged from -0.56% for canagliflozin 300 mg (95% credible interval (CrI): -0.76 to -0.33%), to -0.95% for dapagliflozin 5 mg (95% CrI: -1.20 to -0.69%).
    2 context sentences
    Summary · context
    Randomised controlled trials with ≥20 weeks of treatment evaluating once-weekly semaglutide or SGLT-2is.
    Summary · context
    Fixed-effect and random-effect Bayesian NMA were used to indirectly compare treatment effects at 26 (±4) weeks.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes on 1-2 oral drugs, network meta-analysis found once-weekly semaglutide 1.0 mg reduced weight more than SGLT-2 inhibitors, by 1.35 to 2.48 kg.

    In plain wordsIn adults with type 2 diabetes, indirect comparison found weekly semaglutide led to more weight loss than SGLT-2 inhibitor pills.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change versus SGLT-2 inhibitors
    Study

    n: not reported in source

    Comparator
    SGLT-2 inhibitors
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.0 mg once weekly · 26 (±4) weeksAs given in this study (human).

    Measurements

    Weight mean difference
    −1.35 kg
    vs canagliflozin 300 mg
    Weight mean difference
    −2.48 kg
    vs dapagliflozin 5 mg

    Source sentences

    Summary
    The MD in change from baseline in weight of once-weekly semaglutide 1.0 mg versus SGLT-2is ranged from -1.35 kg for canagliflozin 300 mg to -2.48 kg for dapagliflozin 5 mg
    2 context sentences
    Summary · context
    Randomised controlled trials with ≥20 weeks of treatment evaluating once-weekly semaglutide or SGLT-2is.
    Summary · context
    Fixed-effect and random-effect Bayesian NMA were used to indirectly compare treatment effects at 26 (±4) weeks.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes on 1-2 oral drugs, network meta-analysis found once-weekly semaglutide 1.0 mg lowered fasting plasma glucose more than SGLT-2 inhibitors, by 0.41 to 1.37 mmol/L.

    In plain wordsIn adults with type 2 diabetes, indirect comparison found weekly semaglutide lowered fasting blood sugar more than SGLT-2 inhibitor pills.

    Peptide
    Semaglutide
    Outcome
    DecreaseFasting plasma glucose change versus SGLT-2 inhibitors
    Study

    n: not reported in source

    Comparator
    SGLT-2 inhibitors
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.0 mg once weekly · 26 (±4) weeksAs given in this study (human).

    Measurements

    FPG mean difference
    −0.41 mmol/L
    vs canagliflozin 300 mg
    FPG mean difference
    −1.37 mmol/L
    vs dapagliflozin 5 mg

    Source sentences

    Summary
    change from baseline in fasting plasma glucose ranged from -0.41 mmol/L for canagliflozin 300 mg to -1.37 mmol/L for dapagliflozin 5 mg.
    2 context sentences
    Summary · context
    Randomised controlled trials with ≥20 weeks of treatment evaluating once-weekly semaglutide or SGLT-2is.
    Summary · context
    Fixed-effect and random-effect Bayesian NMA were used to indirectly compare treatment effects at 26 (±4) weeks.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes on 1-2 oral drugs, network meta-analysis found once-weekly semaglutide not statistically different from all SGLT-2 inhibitors in reducing systolic blood pressure.

    In plain wordsIn adults with type 2 diabetes, indirect comparison found no clear difference in blood pressure lowering between weekly semaglutide and SGLT-2 inhibitors.

    Peptide
    Semaglutide
    Outcome
    No significant changeSystolic blood pressure change versus SGLT-2 inhibitors
    Study

    n: not reported in source

    Comparator
    SGLT-2 inhibitors
    Analysis
    Primary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    1.0 mg once weekly · 26 (±4) weeksAs given in this study (human).

    Source sentences

    Summary
    Once-weekly semaglutide was not statistically differentiable than all SGLT-2is in reducing systolic blood pressure.
    2 context sentences
    Summary · context
    Randomised controlled trials with ≥20 weeks of treatment evaluating once-weekly semaglutide or SGLT-2is.
    Summary · context
    Fixed-effect and random-effect Bayesian NMA were used to indirectly compare treatment effects at 26 (±4) weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.